Wellstat gains FDA approval of chemo antidote Vistogard

UK-based specialist health care company BTG (LSE: BTG) says that the US Food and Drug Administration has approved privately-held US firm Wellstat Therapeutics’ Vistogard (uridine triacetate).

Vistogard becomes the first and only drug to treat patients following an overdose of chemotherapy drugs 5-fluorouracil (5-FU) or capecitabine, or in patients exhibiting early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (eg, gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of 5-FU or capecitabine administration. Vistogard received approval following a priority review by the FDA.

Adds to approval for orotic aciduria use